{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:23:54Z","timestamp":1760235834191,"version":"build-2065373602"},"reference-count":35,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,9,26]],"date-time":"2021-09-26T00:00:00Z","timestamp":1632614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Cheng-Hsin General Hospital","award":["CHNDMC-110-18"],"award-info":[{"award-number":["CHNDMC-110-18"]}]},{"DOI":"10.13039\/501100006245","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","award":["MOST 107-2320-B-016-011-MY3"],"award-info":[{"award-number":["MOST 107-2320-B-016-011-MY3"]}],"id":[{"id":"10.13039\/501100006245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Malignant-associated pleural fluid (MAPF) represented an unsolved problem in advanced lung cancer. Our previous work characterized increased pleural angiogenesis in lung adenocarcinoma and the propensity of MAPF on endothelial angiogenesis. This study investigated the combined efficacy of the tyrosine kinase inhibitor (gefitinib) and bevacizumab in opposing MAPF-induced angiogenesis. In lung adenocarcinoma patients with malignant pleural effusion (MPE), Kaplan\u2013Meier analysis revealed the benefit of cotreatment with target therapy and bevacizumab. Increased EGFR expression was observed in the pleural microvessels of patients with lung adenocarcinoma both with and without mutations in EGFR. MAPF was obtained from lung adenocarcinoma patients both wild-type and mutant EGFRs. Total and phosphorylated EGFR were upregulated in HUVEC cultured with MAPF. Treatment with gefitinib as an EGFR inhibitor suppressed MAPF-induced endothelial migration and partially attenuated endothelial proliferation in both wild-type and mutant EGFR lung adenocarcinoma. Cotreatment with gefitinib and bevacizumab produced better inhibition of MAPF-induced endothelial angiogenesis than gefitinib alone in the mutant EGFR subgroup. Protein analysis of MAPF-derived exosomes revealed abundant EGFR and p-EGFR components that implied possible transfer to endothelial cells. Concluding Kaplan\u2013Meier analysis and in vitro studies, the results indicated that the addition of bevacizumab on gefitinib treatment could suppress MAPF-induced angiogenesis in lung adenocarcinoma patients.<\/jats:p>","DOI":"10.3390\/biomedicines9101327","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T01:59:47Z","timestamp":1632707987000},"page":"1327","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Concurrent Blockade of Endothelial EGFR and VEGF Signaling on Malignant Associated Pleural Fluid Induced Angiogenesis: From Clinic to Bench"],"prefix":"10.3390","volume":"9","author":[{"given":"Wei-Teing","family":"Chen","sequence":"first","affiliation":[{"name":"Division of Chest Medicine, Department of Medicine, Cheng-Hsin General Hospital, Taipei 112, Taiwan"},{"name":"Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8382-9820","authenticated-orcid":false,"given":"Yu-Huei","family":"Lin","sequence":"additional","affiliation":[{"name":"Post-Baccalaureate Program in Nursing, College of Nursing, Taipei Medical University, Taipei 110, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Ying","family":"Changchien","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan"},{"name":"Department of Biology and Anatomy, National Defense Medical Center, Taipei 114, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6303-5858","authenticated-orcid":false,"given":"Ying","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Biology and Anatomy, National Defense Medical Center, Taipei 114, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5824-7079","authenticated-orcid":false,"given":"Hsin-Han","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Biology and Anatomy, National Defense Medical Center, Taipei 114, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1085-9014","authenticated-orcid":false,"given":"Wen-Chiuan","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao-Chung","family":"Tsai","sequence":"additional","affiliation":[{"name":"Division of Chest Medicine, Department of Internal Medicine, Tri-Service General Hospital Songshan Branch, Taipei 105, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chieh-Yung","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Sheng","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Taichung Armed Force General Hospital, Taichung 411, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Ting","family":"Cheng","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Liang","family":"Tsai","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2006.04.016","article-title":"Malignant pleural effusion, current and evolving approaches for its diagnosis and management","volume":"54","year":"2006","journal-title":"Lung Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.chest.2020.10.081","article-title":"Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients with Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations","volume":"159","author":"Schwalk","year":"2020","journal-title":"Chest"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","article-title":"Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): Interim analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"20","author":"Saito","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"100826","DOI":"10.1016\/j.tranon.2020.100826","article-title":"Osimertinib regressed an EGFR-mutant lung-adenocarcinoma bone-metastasis mouse model and increased long-term survival","volume":"13","author":"Higuchi","year":"2020","journal-title":"Transl. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/JTO.0000000000000434","article-title":"Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non\u2013small cell lung cancer with activating EGFR gene mutations: The Okayama Lung Cancer Study Group Trial 1001","volume":"10","author":"Ichihara","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1183\/09031936.00167407","article-title":"Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma","volume":"32","author":"Wu","year":"2008","journal-title":"Eur. Respir. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1158\/1541-7786.MCR-06-0404","article-title":"The role of VEGF and EGFR inhibition: Implications for combining anti\u2013VEGF and anti\u2013EGFR agents","volume":"5","author":"Tabernero","year":"2007","journal-title":"Mol. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1158\/0008-5472.CAN-04-3700","article-title":"Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model","volume":"65","author":"Yokoi","year":"2005","journal-title":"Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.mvr.2008.01.002","article-title":"Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells","volume":"76","author":"Amin","year":"2008","journal-title":"Microvasc. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1111\/cas.14584","article-title":"Effect of malignant-associated pleural effusion on endothelial viability, motility and angiogenesis in lung cancer","volume":"111","author":"Changchien","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/cas.14772","article-title":"Distinct JNK\/VEGFR signaling on angiogenesis of breast cancer-associated pleural fluid based on hormone receptor status","volume":"112","author":"Changchien","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1158\/0008-5472.CAN-05-0002","article-title":"A new perspective on tumor endothelial cells: Unexpected chromosome and centrosome abnormalities","volume":"65","author":"Hida","year":"2005","journal-title":"Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"a006536","DOI":"10.1101\/cshperspect.a006536","article-title":"Tumor endothelial cells","volume":"Volume 2","author":"Dudley","year":"2012","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1158\/0008-5472.CAN-05-3387","article-title":"Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors","volume":"66","author":"Amin","year":"2006","journal-title":"Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"vii109","DOI":"10.1093\/annonc\/mdl962","article-title":"Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: A rational approach for multi-target anticancer therapy","volume":"17","author":"Ciardiello","year":"2006","journal-title":"Ann. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1073\/pnas.0804543106","article-title":"Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR","volume":"106","author":"Meehan","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Olejarz, W., Kubiak-Tomaszewska, G., Chrzanowska, A., and Lorenc, T. (2020). Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21165840"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-021-01307-9","article-title":"Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer","volume":"20","author":"Wu","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.biopha.2018.12.088","article-title":"Roles of exosomes in the carcinogenesis and clinical therapy of non-small cell lung cancer","volume":"111","author":"Liu","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_20","first-page":"3","article-title":"Isolation and characterization of exosomes from cell culture supernatants and biological fluids","volume":"30","author":"Amigorena","year":"2006","journal-title":"Curr. Protoc. Cell Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"686","DOI":"10.7150\/jca.34957","article-title":"Efficacy of EGFR-TKIs with or without angiogenesis inhibitors in advanced non-small-cell lung cancer: A systematic review and meta-analysis","volume":"11","author":"Chen","year":"2020","journal-title":"J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"pkaa064","DOI":"10.1093\/jncics\/pkaa064","article-title":"EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Non\u2013Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials","volume":"4","author":"Conforti","year":"2020","journal-title":"JNCI Cancer Spectr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1080\/02841860310017441","article-title":"HER-2, EGFR, COX-2 expression status correlated to microvessel density and survival in resected non-small cell lung cancer","volume":"43","author":"Wester","year":"2004","journal-title":"Acta Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/annonc\/mdh011","article-title":"Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer","volume":"15","author":"Selvaggi","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_25","first-page":"PA4255","article-title":"Epidermal growth factor receptor (EGFR) expression in non-small cell lung carcinoma (NSCLC) and survival","volume":"46","author":"Salimath","year":"2015","journal-title":"Eur. Respir. Soc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ijc.21479","article-title":"Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies","volume":"117","author":"Giaccone","year":"2005","journal-title":"Int. J. Cancer"},{"key":"ref_27","first-page":"3592","article-title":"Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice","volume":"8","author":"Kedar","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-019-0609-x","article-title":"Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake","volume":"2","author":"Ko","year":"2019","journal-title":"Commun. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.1038\/onc.2017.105","article-title":"Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1","volume":"36","author":"Hsu","year":"2017","journal-title":"Oncogene"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"34343","DOI":"10.1074\/jbc.M113.480822","article-title":"Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells","volume":"288","author":"Tadokoro","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"xi146","DOI":"10.1016\/S0923-7534(20)32442-X","article-title":"A Case of Lung Adenocarcinoma with Wild-Type EGFR Malignant Pleural Effusion Well Controlled by Treatment with Gefitinib","volume":"23","author":"Ueda","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1593\/neo.08200","article-title":"Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors","volume":"10","author":"Kuwai","year":"2008","journal-title":"Neoplasia"},{"key":"ref_33","first-page":"PA1596","article-title":"Efficacy of EGFR-TKI for malignant pleural effusion in lung adenocarcinoma patients","volume":"50","author":"Chung","year":"2017","journal-title":"Eur. Respir. Soc."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jamaoncol.2019.1847","article-title":"Effect of erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non\u2013small cell lung cancer: A phase 2 randomized clinical trial","volume":"5","author":"Stinchcombe","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1111\/1759-7714.13472","article-title":"Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B","volume":"11","author":"Noro","year":"2020","journal-title":"Thorac. Cancer"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/10\/1327\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:05:27Z","timestamp":1760166327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/10\/1327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,26]]},"references-count":35,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["biomedicines9101327"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines9101327","relation":{},"ISSN":["2227-9059"],"issn-type":[{"type":"electronic","value":"2227-9059"}],"subject":[],"published":{"date-parts":[[2021,9,26]]}}}